Biomarin awaits crucial approvals and flat growth in 2021

2021 could turn out to be an important year for Biomarin, which expects to get a growth hormone against dwarfism approved on the one hand, while battling health authorities in the US and the EU on the other, as the firm attempts to get approvals for its gene therapy against hemophilia.
Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix
Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix

In 2020, Biomarin's revenue has increased from USD 1.7bn to USD 1.9bn, which is the highest revenue in the history of the still-growing US company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading